Gerald Ponath

Glial cell dysfunction in schizophrenia indicated by increased S100B in the CSF.

1 Roy A. Psychiatr Q 1993; 64: 345–358. 2 Mann JJ In: Bloom FE and Kupfer DJ(eds). Psychopharmacology: The Fourth Generation of Progress. Raven Press: New York, 1995; 1919–1928. 3 Asberg M, Traskman L, Thoren P. Arch Gen Psychiatry 1976; 33: 1193–1197. 4 Nordstrom P, Samuelsson M, Asberg M, Traskman-Bendz L, AbergWistedt A, Nordin C et al. Suicide Life Threat Behav 1994; 24: 1–9. 5 Fitzpatrick PF. Annu Rev Biochem 1999; 68: 355. 6 Rujescu D, Giegling I, Sato T, Hartmann AM, Moller HJ. Biol Psychiatry 2003; 54: 465–473. 7 Walther DJ, Peter JU, Bashammakh S, Hortnagl H, Voits M, Fink H et al. Science 2003; 299: 76. 8 Ono H, Shirakawa O, Kitamura N, Hashimoto T, Nishiguchi N, Nishimura A et al. Mol Psychiatry 2002; 7: 1127–1132. 9 McGuffin P, Katz R. Br J Psychiatry 1989; 155: 294–304. 10 Owens MJ, Nemeroff CB. Clin Chem 1994; 40: 288–295. 11 Nielsen DA, Goldman D, Virkkunen M, Tokola R, Rawlings R, Linnoila M. Arch Gen Psychiatry 1994; 51: 34–38. 12 Mann JJ, Malone KM, Nielsen DA, Goldman D, Erdos J, Gelernter J. Am J Psychiatry 1997; 154: 1451–1453. 13 Du L, Bakish D, Hrdina PD. J Affect Disord 2001; 65: 37–44.

S100B serum levels and long-term improvement of Negative symptoms in patients with schizophrenia

S100B, a calcium-binding protein produced by astroglial cells, mediates paracrine and autocrine effects on neurons and glial cells. It regulates the balance between proliferation and differentiation in neurons and glial cells by affecting protective and apoptotic mechanisms. Post-mortem studies have demonstrated a deficit in synapses and dendrites in brains of schizophrenics. Recent studies have shown increased S100B levels in medicated acutely psychotic schizophrenic patients as well as unmedicated or drug naive schizophrenics. One study reported a positive correlation between negative symptoms and S100B. S100B serum levels (quantitative immunoassay) and psychopathology (Positive and Negative Syndrome Scale, PANSS) were examined upon study admission and after 12 and 24 weeks of standardized treatment in 98 chronic schizophrenic patients with primarily negative symptoms. Compared to age- and sex-matched healthy controls, the schizophrenic patients showed significantly increased S100B concentrations upon admission and after 12 and 24 weeks of treatment. High PANSS negative scores were correlated with high S100B levels. Regression analysis comparing psychopathology subscales and S100B identified negative symptomatology as the predicting factor for S100B. S100B is not just elevated during acute stages of disease since it remains elevated for at least 6 months following an acute exacerbation. With regard to psychopathology, negative symptomatology appears to be the predicting factor for the absolute S100B concentration. This might indicate that S100B in schizophrenic patients either promotes apoptotic mechanisms by itself or is released from astrocytes as part of an attempt to repair a degenerative or destructive process.

S100B in Schizophrenic Psychosis

Recent findings have strengthened the hypothesis that a dysfunction of neuronal synapses and dendrites is relevant for the pathogenesis of schizophrenia. It might be present during neurodevelopment as well as in degenerative and regenerative processes of the mature brain. S1OOB, a small, Ca2+-binding, astrocytic protein, plays an important role in modulating the proliferation and differentiation of neurons and glia cells. It is involved in the regulation of cellular energy metabolism and interacts with many immunological functions of the brain. This review addresses findings from cell cultural and animal experiments potentially pertinent for the pathogenesis of schizophrenic psychoses. Morphological and functional data are analyzed and clinical studies reporting alterations of S1OOB concentrations in schizophrenic patients are reviewed. Evidence and limitations of the available studies are pointed out and promising future research strategies are outlined.

Autocrine S100B effects on astrocytes are mediated via RAGE

To find out if the astrocytic protein S100B involves its autocrine effects via RAGE we investigated the capacity of astrocytes to upregulate IL-6 and TNF-alpha expression by stimulation with S100B. The subcellular localization of RAGE expression at the cell surface membrane of cultured astrocytes was demonstrated by immunofluorescence microscopy, flow cytometry and Western blotting. S100B was able to stimulate IL-6 and TNF-alpha secretion in cultured astrocytes in a concentration- and time-dependent manner as shown by ELISA. S100B induced IL-6 and TNF-alpha secretion was blocked by the use of RAGE siRNA specific for knocking down RAGE expression.

Association between genetic variants of IL-1β, IL-6 and TNF-α cytokines and cognitive performance in the elderly general population of the MEMO-study

This study is to investigate the associations between specific polymorphisms in three cytokine genes and domains of cognitive functioning in a population based study in the elderly. In a cross-sectional study of 369 community dwelling elderly subjects we examined the relationships between the polymorphisms IL-1beta-1418C-->T, IL-6-572G-->C and TNF-alpha-308G-->A and the cognitive function domains memory, processing speed and motor function using an extensive neuropsychological test battery. Linear regression models were used in the analysis and results adjusted for multiple comparisons. A significant association between the IL-1beta-1418C-->T polymorphism and memory performance was found with carriers of the T allele (dominant model) having worse memory performance than those with the C allele. In addition, a significant association between the TNF-alpha-308G-->A polymorphism and processing speed was observed, indicating better performance for heterozygous or homozygous carriers of the A allele. These results remained significant after adjustment for known confounders of cognitive function and additional Bonferroni correction for multiple comparisons. Our study provides first results on detrimental effects of the IL-1beta-1418C-->T polymorphism on memory performance and neuroprotective effects of the TNF-alpha-308G-->A polymorphism on processing speed in elderly individuals. Further research is needed to prospectively examine changes in cognitive performance in relation to cytokine genotypes.

Association between IL-8 cytokine and cognitive performance in an elderly general population - The MEMO-Study

OBJECTIVES To investigate the associations between circulating cytokines and specific neuropsychological domains of cognitive functioning (memory, processing speed and motor function) and general cognitive function (MMSE) in healthy elderly individuals. METHODS In a cross-sectional study of 369 community dwelling elderly subjects, we examined the relationship between serum IL-1beta, sIL-4R, IL-6, IL-8, IL-10, IL-12 and TNF-alpha concentrations and cognitive performance using an extensive standardized and validated cognitive test battery assessing memory, word fluency, perceptual/cognitive speed, attention and executive functioning, and motor speed. RESULTS Multivariate analysis adjusted for various confounders and Bonferroni correction for multiple comparisons demonstrated that increased serum concentrations of IL-8 were associated with poor performance in the memory and speed domains and in motor function. No significant associations were found between the remaining cytokines and domains of cognitive functioning. Global cognitive functioning, as measured with MMSE, was not associated with any cytokine. CONCLUSIONS This study suggests an association between circulating IL-8 concentrations and cognitive dysfunction in the elderly. An interaction between this cytokine and glial cells may help explain the pathophysiological mechanisms leading to cognitive impairment in our study group.

Glial cell activation in a subgroup of patients with schizophrenia indicated by increased S100B serum concentrations and elevated myo-inositol

Post-mortem and in-vivo studies support the hypothesis that astrocytes might be involved in the pathogenesis of schizophrenia. To further substantiate this hypothesis two markers of astroglial activation (myo-inositol, S100B) acquired with independent methods ((1)H-MRS, quantitative immunoassay) were concomitantly measured in schizophrenic patients. Patients with increased S100B levels showed elevated myo-inositol concentrations. This pilot study demonstrates a concomitant elevation of two markers indicating astrocyte activation in a subgroup of schizophrenic patients.

Memory impairment correlates with increased S100B serum concentrations in patients with chronic schizophrenia.

Astrocyte activation indicated by increased S100B is considered a potential pathogenic factor for schizophrenia. To investigate the relationship between astrocyte activation and cognitive performance, S100B serum concentration, memory performance, and psychopathology were assessed in 40 first-episode and 35 chronic schizophrenia patients upon admission and after four weeks of treatment. Chronic schizophrenia patients with high S100B were impaired concerning verbal memory performance (AVLT, Auditory Verbal Learning Test) compared to chronic and first-episode patients with low S100B levels. The findings support the hypothesis that astrocyte activation might contribute to the development of cognitive dysfunction in schizophrenia.

Association Between Cytokines and Cerebral MRI Changes in the Aging Brain

The association between cytokines (IL-1β, sIL-4R, IL-6, IL-8, IL-10, IL-12, TNF-α) and subcortical white matter lesions, cortical atrophy and lacunar infarctions of the aging brain was investigated among 268 elderly community participants. Single pro- and anti-inflammatory cytokines were neither associated with WML nor with atrophy and lacunar infarction. An association between atrophy and the chemokine-cytokine factor (containing sIL-4R, IL-6, IL-8) remained significant after adjustment for age, gender, education, depressive symptoms, diabetes mellitus, cardiovascular diseases (stroke, TIA, myocardial infarction, myocardial insufficiency, arrhythmic heart), hypertension, body-mass index, smoking status and aggregation inhibitors as opposed to single cytokines. Atrophy of the parietal, temporal and occipital lobes was associated with the same cytokinechemokine factor for both the whole sample or restricted to those without history of stroke/TIA. The results indicate that a combination of chemokine-cytokines rather than single cytokines may contribute to inflammatory processes associated with cortical atrophy in the aging brain.

Risk Variants in the S100B Gene Predict Elevated S100B Serum Concentrations in Healthy Individuals

Several lines of evidence suggest an important role of the S100B protein and its coding gene in different neuropathological and psychiatric disorders like dementia, bipolar affective disorders and schizophrenia. To clarify whether a direct link exists between gene and gene product, that is, whether S100B variants directly modulate S100B serum concentration, 196 healthy individuals were assessed for S100B serum concentrations and genotyped for five potentially functional S100B SNPs. Functional variants of the serotonergic genes 5‐HT1A and 5‐HTT possibly modulating S100B serum levels were also studied. Further, publicly available human postmortem gene expression data were re‐analyzed to elucidate the impact of S100B, 5‐HT1A and 5‐HTT SNPs on frontal cortex S100B mRNA expression. Several S100B SNPs, particularly rs9722, and the S100B haplotype T‐G‐G‐A (including rs2186358‐rs11542311‐rs2300403‐rs9722) were associated with elevated S100B serum concentrations (Bonferroni corrected P < 0.05). Of these, rs11542311 was also associated with S100B mRNA expression directly (Bonferroni corrected P = 0.05) and within haplotype G‐A‐T‐C (rs11542311‐rs2839356‐rs9984765‐rs881827; P = 0.004), again with the G‐allele increasing S100B expression. Our results suggest an important role of S100B SNPs on S100B serum concentrations and S100B mRNA expression. It hereby links recent evidence for both, the impact of S100B gene variation on various neurological or psychiatric disorders like dementia, bipolar affective disorders and schizophrenia and the strong relation between S100B serum levels and these disorders.